A recent analysis presented at the American Society for Metabolic and Bariatric Surgery (ASMBS2026) meeting, drawn from the Epic Cosmos database of nearly 20 million patients, reveals a stark reality: despite a dramatic rise in GLP-1 agonist prescriptions from under 4,600 in 2018 to over 1.4 million in 2025, and a modest peak in bariatric surgeries at 43,000 in 2023 before a decline to under 40,000 in 2025, 90-95% of individuals with severe obesity receive no treatment at all. This study, focused exclusively on patients without diabetes, signals a persistent public health crisis that mainstream coverage often glosses over in favor of celebrating therapeutic advances. While the original report highlights the exponential growth of GLP-1 use (from 0.03% to 5.3% of eligible patients) and the concerning dip in surgical interventions (from 0.24% in 2023 to 0.21% in 2025), it misses deeper systemic issues and fails to contextualize these trends within broader patterns of healthcare inequity.

First, the decline in bariatric surgery, particularly among those with the highest disease severity as noted by lead author Jeffery Reeves, MD, raises critical questions about patient decision-making and access. Are patients opting for GLP-1s due to perceived lower risk or cost, or are structural barriers—such as limited surgical centers or insurance denials—driving this shift? A 2022 study published in JAMA Surgery (DOI:10.1001/jamasurg.2022.0257) found that only 3.7% of eligible patients in a cohort of over 1.5 million received bariatric surgery, with significant disparities by race, income, and geography (observational study, large sample size, no conflicts of interest reported). This suggests that the recent dip may not be a simple preference for GLP-1s but a reflection of entrenched inequities, a nuance the original coverage overlooks.

Second, the untreated majority—90-95% of patients—points to a failure beyond individual choice or drug availability. The original article mentions barriers like insurance coverage and stigma, but it underplays the role of policy and healthcare infrastructure. For instance, a 2023 report in Obesity Reviews (DOI:10.1111/obr.13584) highlights that only 22 states in the U.S. mandate private insurance coverage for bariatric surgery, and even fewer cover GLP-1s for obesity without comorbidities like diabetes (review study, no sample size, potential bias from industry-funded authors). This patchwork coverage, combined with high out-of-pocket costs (GLP-1s can exceed $1,000 monthly without insurance), means that even as prescriptions climb, they reach only a privileged fraction. The original story’s focus on raw numbers misses how these treatments remain a luxury for many.

Finally, the cultural narrative around obesity as a personal failing, rather than a chronic disease requiring systemic intervention, continues to hinder progress. While GLP-1s are often framed as a 'game-changer,' their rise coincides with stagnant public health efforts to address upstream factors like food insecurity or sedentary environments—issues that disproportionately affect low-income populations with severe obesity. The ASMBS data shows a treatment gap that mirrors broader health disparities, a connection absent from the initial report. Synthesizing these sources, it’s clear that while GLP-1s offer hope, they are not a panacea for a crisis rooted in access, policy, and social determinants of health.

The bigger picture is a call to action: without addressing coverage gaps, expanding surgical capacity, and destigmatizing obesity care, the untreated majority will persist. This isn’t just a story of new drugs or declining surgeries—it’s a mirror to a healthcare system failing its most vulnerable.